Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis
Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn’s disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) d...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2008/493405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565455074623488 |
|---|---|
| author | Remo Panaccione Richard N Fedorak Guy Aumais Edmond-Jean Bernard Charles N Bernstein Alain Bitton Ken Croitoru Levinus A Dieleman Robert Enns Brian G Feagan Denis Franchimont Gordon R Greenberg Anne-Marie Griffiths John K Marshall Pierre Pare Sunil Patel Robert Penner Craig Render Ernest Seidman A Hillary Steinhart |
| author_facet | Remo Panaccione Richard N Fedorak Guy Aumais Edmond-Jean Bernard Charles N Bernstein Alain Bitton Ken Croitoru Levinus A Dieleman Robert Enns Brian G Feagan Denis Franchimont Gordon R Greenberg Anne-Marie Griffiths John K Marshall Pierre Pare Sunil Patel Robert Penner Craig Render Ernest Seidman A Hillary Steinhart |
| author_sort | Remo Panaccione |
| collection | DOAJ |
| description | Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn’s disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn’s disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients. Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members’ clinical experiences. |
| format | Article |
| id | doaj-art-8599be4e6b0d4a07a1282e835b9551d1 |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-8599be4e6b0d4a07a1282e835b9551d12025-02-03T01:07:33ZengWileyCanadian Journal of Gastroenterology0835-79002008-01-0122326127210.1155/2008/493405Review and Clinical Perspectives for the Use of Infliximab in Ulcerative ColitisRemo Panaccione0Richard N Fedorak1Guy Aumais2Edmond-Jean Bernard3Charles N Bernstein4Alain Bitton5Ken Croitoru6Levinus A Dieleman7Robert Enns8Brian G Feagan9Denis Franchimont10Gordon R Greenberg11Anne-Marie Griffiths12John K Marshall13Pierre Pare14Sunil Patel15Robert Penner16Craig Render17Ernest Seidman18A Hillary Steinhart19University of Calgary, Calgary, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of Montreal, Montreal, Quebec, CanadaUniversity of Montreal, Montreal, Quebec, CanadaUniversity of Manitoba, Winnipeg, Manitoba, CanadaMcGill University, Montreal, Quebec, CanadaMcMaster University, Hamilton, Ontario, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of British Columbia, Vancouver, British Columbia, CanadaUniversity of Western Ontario, London, CanadaMcGill University, Montreal, Quebec, CanadaUniversity of Toronto, Toronto, Ontario, CanadaUniversity of Toronto, Toronto, Ontario, CanadaMcMaster University, Hamilton, Ontario, CanadaLaval University, Quebec City, Quebec, CanadaDalhousie University, Halifax, Nova Scotia, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaUniversity of Alberta, Edmonton, Alberta, CanadaMcGill University, Montreal, Quebec, CanadaUniversity of Toronto, Toronto, Ontario, CanadaInfliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients with Crohn’s disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn’s disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations regarding infliximab that address the needs of clinicians and UC patients. Where there is a lack of evidence-based information, the expert panel provides its combined opinion derived from the members’ clinical experiences.http://dx.doi.org/10.1155/2008/493405 |
| spellingShingle | Remo Panaccione Richard N Fedorak Guy Aumais Edmond-Jean Bernard Charles N Bernstein Alain Bitton Ken Croitoru Levinus A Dieleman Robert Enns Brian G Feagan Denis Franchimont Gordon R Greenberg Anne-Marie Griffiths John K Marshall Pierre Pare Sunil Patel Robert Penner Craig Render Ernest Seidman A Hillary Steinhart Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis Canadian Journal of Gastroenterology |
| title | Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis |
| title_full | Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis |
| title_fullStr | Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis |
| title_full_unstemmed | Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis |
| title_short | Review and Clinical Perspectives for the Use of Infliximab in Ulcerative Colitis |
| title_sort | review and clinical perspectives for the use of infliximab in ulcerative colitis |
| url | http://dx.doi.org/10.1155/2008/493405 |
| work_keys_str_mv | AT remopanaccione reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT richardnfedorak reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT guyaumais reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT edmondjeanbernard reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT charlesnbernstein reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT alainbitton reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT kencroitoru reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT levinusadieleman reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT robertenns reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT briangfeagan reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT denisfranchimont reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT gordonrgreenberg reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT annemariegriffiths reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT johnkmarshall reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT pierrepare reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT sunilpatel reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT robertpenner reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT craigrender reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT ernestseidman reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis AT ahillarysteinhart reviewandclinicalperspectivesfortheuseofinfliximabinulcerativecolitis |